The popularity of Sildenafil initially sparked a period of growth for major pharmaceutical companies, but recent developments present a uncertain scenario for shareholders. Generic competitors are eating into earnings, https://idavpmc240508.gynoblog.com/39944546/the-blue-pill-and-pharma-a-volatile-investment